Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after the rare-disease drug developer reported 2023 fourth-quarter earnings, which caused the market to dump its shares to the tune of 13%.
Here's what Shoenhaus could be thinking will catalyze a reversal for this stock.
In January, Recursion made an interesting decision regarding one of the assets it's developing in its fibrotic disease collaboration with .
Source Fool.com
Bayer AG Stock
€27.48
1.480%
We see a rather positive sentiment for Bayer AG with 15 Buy predictions and 1 Sell predictions.
With a target price of 50 € there is a hugely positive potential of 81.98% for Bayer AG compared to the current price of 27.48 €.
